deferiprone has been researched along with Pregnancy in 5 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We concluded that pregnancy is not a contraindication in beta-thalassemia major; complex individual care is needed to achieve a safe outcome for the mother." | 5.51 | A case of post-splenectomy transfusion-dependent homozygous beta-thalassemia major complicated with myocardial siderosis and osteoporosis and usage of iron-chelating therapy with deferiprone in pregnancy. ( Abu, MA; Ahmad, MF; Arsad, N; Chew, KT; Omar, MH; Shafiee, MN; Zakaria, NZ, 2019) |
| "In our study, chelation treatment during pregnancy did not prevent the delivery of healthy children." | 5.43 | Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic? ( Agapidou, A; Diamantidis, MD; Fotiou, P; Manafas, A; Neokleous, N; Vetsiou, E; Vlachaki, E, 2016) |
| "Iron chelating agents - deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX) - are used to treat chronic iron overload in patients with β-thalassemia in an attempt to reduce morbidity and mortality related to siderosis." | 4.93 | Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia. ( El Rassi, F; Saliba, AN; Taher, AT, 2016) |
| " The introduction of effective chelation therapy protocols using primarily deferiprone (L1) in combination with deferoxamine (DFO) resulted in the reduction of iron overload induced cardiac failures, which is the main cause of death in thalassemia major." | 3.75 | Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications. ( Kolnagou, A; Kontoghiorghes, GJ, 2009) |
| "We concluded that pregnancy is not a contraindication in beta-thalassemia major; complex individual care is needed to achieve a safe outcome for the mother." | 1.51 | A case of post-splenectomy transfusion-dependent homozygous beta-thalassemia major complicated with myocardial siderosis and osteoporosis and usage of iron-chelating therapy with deferiprone in pregnancy. ( Abu, MA; Ahmad, MF; Arsad, N; Chew, KT; Omar, MH; Shafiee, MN; Zakaria, NZ, 2019) |
| "In our study, chelation treatment during pregnancy did not prevent the delivery of healthy children." | 1.43 | Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic? ( Agapidou, A; Diamantidis, MD; Fotiou, P; Manafas, A; Neokleous, N; Vetsiou, E; Vlachaki, E, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmad, MF | 1 |
| Zakaria, NZ | 1 |
| Arsad, N | 1 |
| Chew, KT | 1 |
| Abu, MA | 1 |
| Shafiee, MN | 1 |
| Omar, MH | 1 |
| Saliba, AN | 1 |
| El Rassi, F | 1 |
| Taher, AT | 1 |
| Diamantidis, MD | 1 |
| Neokleous, N | 1 |
| Agapidou, A | 1 |
| Vetsiou, E | 1 |
| Manafas, A | 1 |
| Fotiou, P | 1 |
| Vlachaki, E | 1 |
| Kolnagou, A | 1 |
| Kontoghiorghes, GJ | 1 |
| Shilalukey, K | 1 |
| Kaufman, M | 1 |
| Bradley, S | 1 |
| Francombe, WH | 1 |
| Amankwah, K | 1 |
| Goldberg, E | 1 |
| Shear, N | 1 |
| Olivieri, NF | 1 |
| Koren, G | 1 |
1 review available for deferiprone and Pregnancy
| Article | Year |
|---|---|
Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Topics: Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Disease Mana | 2016 |
4 other studies available for deferiprone and Pregnancy
| Article | Year |
|---|---|
A case of post-splenectomy transfusion-dependent homozygous beta-thalassemia major complicated with myocardial siderosis and osteoporosis and usage of iron-chelating therapy with deferiprone in pregnancy.
Topics: beta-Globins; beta-Thalassemia; Blood Transfusion; Cardiomyopathies; Deferiprone; Female; Homozygote | 2019 |
Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Femal | 2016 |
Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications.
Topics: Chelation Therapy; Chronic Disease; Cyprus; Deferiprone; Deferoxamine; Female; Ferritins; Genetic Te | 2009 |
Counseling sexually active teenagers treated with potential human teratogens.
Topics: Adolescent; Adolescent Behavior; Anemia, Sickle Cell; beta-Thalassemia; Contraception Behavior; Coun | 1997 |